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Abstract
Background. An increase in gastric mucosal lesions due to 
nonsteroidal antiinﬂ  ammatory drugs (NSAIDs) has been 
reported along with the aging of society; even orthopedic 
surgeons can no longer remain unconcerned about this disease. 
However, no study has accurately examined the incidence of 
gastric mucosal lesions; therefore, adequate evidence has not 
been established. In this study, endoscopic examinations were 
performed to determine the status of gastric mucosal lesions 
in patients receiving long-term NSAID therapy.
Methods. In 261 patients receiving NSAIDs other than aspirin 
for more than 28 days, excluding external application, upper 
gastrointestinal endoscopy was performed regardless of any 
subjective symptoms after obtaining the patient’s medical 
history. The severity of the gastric mucosal lesions was evalu-
ated using the modiﬁ  ed Lanza score. Patient factors involved 
in the development of lesions were examined using a logistic 
regression analysis with criterion variables of gastric mucosal 
lesions and ulcers and the factors of sex, age, Helicobacter 
pylori  infection, and type of NSAID as candidates for the 
explanatory variable.
Results. Gastric mucosal lesions were observed in 164 patients 
(62.8%); 27 (10.3%) had ulcers. The use of diclofenac, subjec-
tive symptoms, irregular lifestyle, and increased body mass 
index (BMI) were four factors associated with the develop-
ment of gastric mucosal lesions; the odds ratios were 2.99, 
1.92, 1.80, and 1.09, respectively. Also, the use of diclofenac, 
presence of H. pylori, irregular lifestyle, alcohol consumption, 
and aging were ﬁ  ve factors associated with the development 
of ulcers; the odds ratios were 6.40, 6.07, 2.62, 2.06, and 1.05, 
respectively.
Conclusions.  Diclofenac can cause gastric mucosal lesions, 
including ulcers, more easily than other NSAIDs. H. pylori 
infection is a high-risk factor for ulcers in patients receiving 
long-term NSAIDs therapy. In NSAID-treated patients, sub-
jective symptoms are not grounds for a diagnosis of gastric 
mucosal lesions, especially ulcers.
Introduction
Nonsteroidal antiinﬂ  ammatory drugs (NSAIDs) have a 
long history. Aspirin was synthesized as the ﬁ  rst NSAID 
a century ago, and since then several types of NSAID 
have been developed. NSAIDs have excellent analgesic 
action with high safety; therefore, they are used to treat 
pain with many diseases. In the area of orthopedics, 
long-term NSAID therapy is prescribed not only for 
patients with acute conditions, such as trauma, but also 
for the treatment of chronic diseases, such as arthropa-
thies, including rheumatoid arthritis and low back pain. 
However, gastric mucosal lesions have long been identi-
ﬁ  ed as a side effect of NSAIDs.
1 Many orthopedists 
recognize the side effect but do not attach great impor-
tance to it. In the United States, however, it is estimated 
that 100 000 or more people are admitted to the hospital 
because of gastric mucosal lesions due to NSAIDs, with 
15 000 or more cases resulting in mortality.
2 In a future, 
rapidly aging society, the number of patients with such 
diseases as osteoarthrosis, spondylosis deformans, and 
osteoporosis can be expected to increase, leading to an 
accelerated increase in the use of NSAIDs. Therefore, 
the signiﬁ  cance of NSAIDs-induced gastric mucosal 
lesions will increase, and understanding the actual state 
of NSAIDs-induced gastric mucosal lesions will be 
clinically critical.
Shiokawa et al. described a study of 1008 patients 
receiving long-term NSAID therapy who underwent 
upper gastrointestinal (GI) endoscopy for gastric 
mucosal lesions.
3 Overall, lesions were observed in 627 
patients (62.2%), including gastric ulcers in 156 patients 
(15.5%) and gastritis in 388 patients (38.5%), indicating 
that the incidence of gastric mucosal lesions was high 
in patients receiving NSAID therapy. However, there 
have been few investigations of this issue in Japan. In 
particular, there are many uncertainties about the actual 
state of gastric mucosal lesions due to NSAIDs, which 
have been used widely in recent years.
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Under these circumstances, we compared the thera-
peutic effects of famotidine and rebamipide for gastric 
mucosal lesions (bleeding and erosion) in patients 
receiving long-term NSAID therapy (FORCE study).
4 
In this study, the development of gastric mucosal lesions 
was examined in detail in patients receiving long-term 
NSAID therapy based on the results of upper GI endos-
copy for screening prior to this study.
Materials and method
A multicenter study was conducted from May 2004 to 
July 2005 by gastroenterologists and orthopedists from 
the Nara Medical University and its four associated 
institutions: Nara Prefectural Nara Hospital, Nara Pre-
fectural Gojo Hospital, Kokuho Central Hospital, and 
Nishi Nara Chuo Hospital. The protocol was approved 
by the institutional review boards of all participating 
institutions. The study was conducted in compliance 
with good clinical practices, and written informed 
consent was obtained from all study participants.
Materials
Subjects were outpatients with ages ranging between 20 
and 74 years who were receiving any NSAID other than 
aspirin, excluding external application, for more than 4 
weeks. Patients receiving any agent, including histamine 
receptor antagonists, proton pump inhibitors, musca-
rinic receptor antagonists, and prostaglandins within 4 
weeks before the endoscopy were excluded. Addition-
ally, patients were excluded if any change in regimen, 
including dosage and administration, of NSAIDs or 
disease-modifying antirheumatic drugs (DMARDs) 
occurred within 4 weeks before the endoscopy. In addi-
tion, patients were excluded if there was any change 
in the regimen of adrenocortical hormones, excluding 
external application, within 14 days before the 
endoscopy.
Method
After a complete medical history was obtained from 
patients who gave consent, a urinary anti-H. pylori anti-
body test (enzyme-linked immunosorbent assay) was 
performed followed by endoscopy regardless of subjec-
tive symptoms. A modiﬁ  ed Lanza score (referred to as 
a Lanza score),
5 a scoring system reported by Lanza,
6 
was used for evaluation of endoscopic ﬁ  ndings.
Investigations and statistical analyses
The development of gastric mucosal lesions was tabu-
lated on the basis of the Lanza score according to endo-
scopic ﬁ  ndings. Then patient factors involved in the 
development of lesions were tested using a logistic 
regression analysis where gastric mucosal lesions (Lanza 
score 0 or 1–5) and ulcers (Lanza score 0–4 or 5) were 
criterion variables, and sex and age, presence of H. 
pylori infection, type of NSAID, and subjective symp-
toms were candidates for explanatory variables. “Life-
style,” one of the candidate explanatory variables, 
was subjectively self-assessed by subjects in interview 
surveys. They were asked to assess their daily life pattern 
(e.g., bedtime, hour of rising, and mealtimes) in three 
grades: regular, almost regular, and irregular. In the 
logistic regression, in a stepwise manner, the odds ratio 
and 95% conﬁ  dence interval (95% CI) were calculated 
for selected explanatory variables according to the 
inclusion criteria for the explanatory variable as P < 0.1. 
The P value was calculated using the Wald test, and P 
< 0.05 was considered statistically signiﬁ  cant.
Results
Patients’ medical history
Consent was obtained from 290 patients. Among them, 
21 patients withdrew consent before the endoscopy, 7 
met the exclusion criterion, and 1 died of other causes; 
therefore, 261 patients underwent endoscopy. Their 
medical histories are shown in Table 1, according to the 
factors used as candidates for explanatory variables in 
the logistic regression analysis.
Patients ranged in age from 20 to 74 years (mean 
58.2 years) with a mean body mass index (BMI) of 
23.0 kg/m
2. Underlying diseases included rheumatoid 
arthritis in 100 patients (38.3%), osteoarthritis in 37 
patients (14.2%), and other diseases in 124 patients 
(47.5%). A history of ulcers was noted in 42 patients 
(16.1%), and the anti-H. pylori  antibody test before 
endoscopy revealed that 166 patients (63.6%) were 
positive.
The details of administered NSAIDs and combined 
mucosal protective agents and DMARDs, including 
duplication due to combination, are described as 
follows: Among the NSAIDs, 94 patients (36.0%) re-
ceived loxoprofen, 36 (13.8%) received diclofenac, 34 
(13.0%) received sustained-release diclofenac capsule 
(diclofenac SR), 42 (16.1%) received a preferential 
cyclooxygenase-2 (COX-2 inhibitor; meloxicam or 
etodolac), and 64 (24.5%) received others. Mucosal 
protective agents, mainly teprenone in 103 (39.5%) and 
rebamipide in 74 (28.4%), were administered in combi-
nation with others in 250 of 261 (95.8%) patients. 
DMARDs were administered in 93 patients (35.6%) in 
combination with others, including bucilamine in 54 
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Details of gastric mucosal lesions
Altogether, 164 (62.8%) patients had gastric mucosal 
lesions, of which ulcers (Lanza score 5) were observed 
in 27 (10.3%) and bleeding and erosion (Lanza score 
1–4) in 137 (52.5%). The Lanza score was 1 in 26 
(10.0%), 2 in 23 (8.8%), 3 in 59 (22.6%), and 4 in 29 
(11.1%). There were only 97 patients (37.2%) with no 
lesions (Lanza score 0).
The frequency of gastric mucosal lesions for each 
type of NSAID was as follows: 83.3% (30/36) in patients 
receiving diclofenac, 73.5% (25/34) in those receiving 
diclofenac SR, 58.5% (55/94) in those receiving loxo-
profen, and 54.8% (23/42) in those receiving a prefer-
ential COX-2 inhibitor. When the subjects were divided 
according to the presence of H. pylori  infection, the 
incidence of gastric mucosal lesions was 60.2% (100/166) 
in H. pylori-positive patients and 67.4% (64/95) in H. 
pylori-negative patients. The incidence of ulcers was 
14.5% (24/166) in H. pylori-positive patients and only 
3.2% (3/95) in H. pylori-negative patients. When the 
incidence of gastric mucosal lesions with or without 
subjective symptoms was examined, 74.0% (54/73) of 
patients with subjective symptoms had gastric mucosal 
lesions, and 58.5% (110/188) of those without subjective 
symptoms had gastric mucosal lesions.
The incidence of gastric mucosal lesions was 60.9% 
(53/87) in those aged ≥65 years and 63.8% (111/174) in 
those  <65 years. When patients were stratiﬁ  ed into 
short- or long-term NSAID therapy, the incidence was 
72.2% (39/54) for those receiving therapy for 1–3 months 
and 60.4% (125/207) for those receiving therapy for ≥3 
months.
Results of logistic regression analysis
The following are the results of the logistic regression 
analysis where the criterion variables were gastric 
mucosal lesions and ulcers, and the factors in the medical 
history shown in Table 1 were candidates for explana-
tory variables. Patient factors involved in the patho-
genesis of gastric mucosal lesions included the use 
of diclofenac, history of ulcers, subjective symptoms, 
timing of the initiation of NSAIDs, lifestyle, dosage of 
NSAIDs, and BMI, of which the use of diclofenac, sub-
jective symptoms, lifestyle, and BMI were signiﬁ  cant 
(Fig. 1). The odds ratios (95% CI) of the four factors 
were 2.99 (1.15–7.77) (P  =  0.025) between patients 
taking diclofenac and those who did not, 1.92 (1.00–
3.66) (P = 0.049) between those with and without sub-
jective symptoms, 1.80 (1.15–2.81) (P = 0.011) among 1° 
differences in irregularity of lifestyle, and 1.09 (1.00–
1.19) (P = 0.040) among 1 kg/m
2 differences in BMI.
Patient factors involved in the pathogenesis of ulcers 
included the use of diclofenac, H. pylori infection, use 
Table 1.  Patients’ medical histories (n = 261, candidates for 
explanatory variable for logistic regression analysis )
Factors in medical history  No.  %
Sex
  Female 171  65.5
Underlying diseases
  Rheumatoid arthritis  100  38.3
  Osteoarthritis   37  14.2
  Others 124  47.5
Anti-H. pylori antibody
  Positive 166  63.6
Peptic ulcer history
  Yes   42  16.1
Subjective symptoms
  Yes   73  28.0
Smoking habit
  Yes   62  23.8
Alcohol habit
a
  No 162  62.1
  Occasionally   69  26.4
  Daily   30  11.5
Coffee habit
  Yes 216  82.8
Lifestyle
a
  Regular   82  31.4
  Almost regular  152  58.2
  Irregular   26  10.0
  Unknown   1    0.4
Particular stress
  Yes   57  21.8
  Unknown   2    0.8
Type of NSAIDs
b
  Loxoprofen   94  36.0
  Preferential COX-2 inhibitor
c    42 16.1
  Diclofenac   36  13.8
  Diclofenac SR    34  13.0
  Others   64  24.5
NSAIDs administration
  1–3 months    54  20.7
  > 3 months  207  79.3
Dosage of NSAIDs
a
  Below usual dose    68  26.1
  Usual dose  169  64.8
  Double or combination
d   24   9.2
Type of mucosal protective agents
b
  Teprenone 103  39.5
  Rebamipide   74  28.4
Type of DMARDs
b
  Bucilamine   54  20.7
  Methotrexate   45  17.2
Bisphosphonate
  Yes   17    6.5
Steroids
  Yes   49  18.8
The mean and range of all patients’ ages are 58.2 years and 20.0–74.0 
years, respectively; the mean and range of all patients’ BMI (kg/m
2) 
are 23.0 and 14.7–33.6, respectively
NSAIDs, nonsteroidal antiinﬂ  ammatory drugs; DMARDs, disease-
modifying antirheumatic drugs
a Factors used as continuous variables in multi-logistic regression 
analysis. (The rest are discrete variables)
b Including duplication due to combination
c Meloxicam (n = 34) + Etodolac (n = 8)
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of steroid, lifestyle, alcohol consumption, age, and 
coffee consumption, of which a signiﬁ  cant association 
was conﬁ  rmed in the use of diclofenac, H. pylori infec-
tion, lifestyle, alcohol consumption, and age (Fig. 2). 
The odds ratios (95% CI) of the ﬁ  ve factors were 6.40 
(2.28–17.95) (P  <  0.001) between patients taking/not 
taking diclofenac, 6.07 (1.57–23.46) (P = 0.009) between 
positive and negative for H. pylori infection, 2.62 (1.24–
5.51) (P = 0.011) among 1° differences in irregularity of 
lifestyle, 2.06 (1.16–3.68) (P = 0.014) among 1° differ-
ences in the frequency of alcohol consumption, and 1.05 
(1.00–1.11) (P  =  0.042) among 1 year differences in 
age.
Discussion
NSAIDs may injure the gastric and duodenal mucosa, 
given the pharmacological mechanism of inhibition of 
prostaglandin synthesis,
7  which could be conﬁ  rmed 
through endoscopy. In Japan, Shiokawa et al. reported 
that the incidence of ulcers was approximately 15%.
3 
NSAIDs have been partly devised in the area of the 
drug delivery system (DDS) in their history of develop-
ment, and most orthopedists presume that gastric 
mucosal lesions due to NSAIDs may be clinically less 
important if mucosal protective agents are administered 
concomitantly.
In this epidemiological study, mucosal protective 
agents were concomitantly administered in 250 (95.8%) 
of the 261 patients. Despite this, surprisingly, gastric 
mucosal lesions were observed in 62.8% of patients. 
Although no study using the Lanza score has been con-
ducted in Japan on the incidence of gastric mucosal 
lesions in healthy individuals, the Japanese Society of 
Gastroenterological Cancer Screening reported that the 
incidence of gastric ulcers was 1.04%
8  (Lanza score 
grade 5). Comparison between this ﬁ  gure and the one 
obtained in this study (10.3%) implies that the inci-
dence of gastric ulcers is higher in patients receiving 
NSAIDs. Therefore, orthopedists should recognize the 
importance of gastric mucosal lesions due to NSAIDs, 
especially in patients receiving long-term NSAID 
therapy, and pay close attention to lesions.
H. pylori infection is one of the two major risk factors 
for an ulcer, along with NSAIDs.
9,10 As indicated in this 
diclofenac
yes vs.no
ulcer history
yes vs. no
symptoms
yes vs. no
NSAIDs administration
1-3 months vs. >3months
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irregular-almost regular-regular
dosage of NSAIDs
double or combination
-usual dose-below usual dose
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p value
Fig. 1.  Patient factors involved in the 
pathogenesis of gastric mucosal lesions
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Fig. 2.  Patient factors involved in the 
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study, NSAIDs are an independent risk factor for gastric 
mucosal lesions regardless of H. pylori infection; that is, 
patients receiving NSAIDs are always at risk for gastric 
mucosal lesions regardless of their medical history.
On the other hand, there is no deﬁ  nite correlation 
between NSAIDs and H. pylori  infection in the 
development of peptic ulcers. In this study, H. pylori 
infection was considered a risk factor for peptic ulcers 
in patients receiving NSAIDs, whereas gastric mucosal 
lesions were not. The results may be interpreted as 
NSAIDs having a signiﬁ  cant inﬂ  uence on the gastric 
mucosa sufﬁ  cient to mask the inﬂ  uence of H. pylori 
infection rather than H. pylori infection inhibiting 
the increased risk of gastric mucosal lesions due to 
NSAIDs. However, it would be rash to conclude that 
NSAIDs are a more important risk factor for gastric 
mucosal lesions than H. pylori infection based only on 
the results of this study; further investigations are 
needed.
The result that H. pylori infection is a risk factor for 
peptic ulcers in patients receiving NSAIDs is consistent 
with the results by Chan et al.
11 The detailed mecha-
nisms by which H. pylori infection increases peptic ulcer 
risks in patients receiving NSAIDs are not fully under-
stood. However, it is likely that vulnerable mucosa with 
chronic inﬂ  ammation caused by H. pylori infection is 
more susceptible to NSAIDs, injurious substances, than 
healthy mucosa. It has been suggested that, in addition 
to NH3 and other injurious substances produced by H. 
pylori, inﬂ  ammatory cell inﬁ  ltration as a response to 
bacterial infection and the associated cytokines and free 
radicals are involved in the mechanisms of gastric 
mucosal lesions caused by H. pylori infection.
12  It is 
likely that the incidence of peptic ulcers increases 
when NSAIDs, which are prostaglandin inhibitors
13 and 
directly injurious,
14  are administered to patients with 
gastric mucosa affected by various injurious factors 
caused by H. pylori  infection. Furthermore, delayed 
healing of ulcers was reported in patients who took 
acid-suppressant drugs while continuing to take 
NSAIDs.
15 Thus, administration of NSAIDs certainly 
has harmful effects on patients with peptic ulcers. As 
described above, and although no conclusions can be 
drawn, the results of the study can serve as a warning 
about drug selection for patients with H. pylori 
infection.
The risk of gastric mucosal lesions in patients with 
subjective symptoms increased less than twice, showing 
that subjective symptoms were not a signiﬁ  cant risk 
factor for peptic ulcers. Indeed, the prevalence of gastric 
mucosal lesions reached 58.5% in patients without sub-
jective symptoms, where 10.1% had peptic ulcers. This 
means that in patients receiving NSAIDs subjective 
symptoms are not a basis for the diagnosis of gastric 
mucosal lesions, especially peptic ulcers. This supports 
previous reports that many gastric mucosal lesions due 
to NSAIDs are asymptomatic.
3,16,17
In this study, lifestyle was selected as one of the risk 
factors for gastric mucosal lesions including peptic 
ulcers. Although lifestyle was based on the subjective 
opinions of patients without an objective evaluation, 
lifestyle was suggested as a possible risk factor for 
gastric mucosal lesions if a patient considered his or her 
lifestyle irregular. There have been reports that irregu-
lar lifestyle, which cannot be an independent risk factor 
for peptic ulcer, can cause not only peptic ulcers but also 
severe consequences, such as hematemesis, when other 
risk factors,  such as H. pylori infection, are added,
18 
suggesting that exercising caution in terms of lifestyle 
habits, such as alcohol ingestion and smoking, for 
patients receiving NSAIDs, may be worthwhile.
As another risk factor for gastric mucosal lesions, 
including peptic ulcers, diclofenac, which is generally 
considered to have a potent antiinﬂ  ammatory analgesic 
effect, was selected. Diclofenac is conventionally known 
to provide a higher risk of upper GI hemorrhage than 
any other NSAIDs
19; therefore, close attention should 
be paid to its use while a superior analgesic effect is 
expected. Although the results of this study cannot 
demonstrate whether there are differences in risks for 
gastric mucosal lesions among the NSAIDs other than 
diclofenac, conventional NSAIDs including loxoprofen, 
meloxicam, and etodolac, which are considered prefer-
ential COX-2 inhibitors and cause fewer gastric mucosal 
lesions, could unexpectedly cause gastric mucosal lesions 
in more than half of patients. Because NSAIDs such as 
meloxicam and etodolac are not designed to target 
COX-2, they are not true COX-2 selective inhibitors. 
No signiﬁ  cant difference was reported between meloxi-
cam and piroxicam, a conventional NSAID, in terms 
of the incidence of gastric mucosal lesions in a study 
in which patients were endoscopically examined after 
meloxicam (15 mg/day, a dosage approved in Japan) or 
piroxicam (20 mg/day) was administered for 1 month.
20 
Therefore, studies must be conducted in patients receiv-
ing COX-2 selective inhibitors, such as celecoxib, before 
the association between COX-2 selective inhibitors and 
gastric mucosal lesions is determined in Japan.
Within the scope of this study, there was no increase 
in the risk for gastric mucosal lesions, which depended 
on the period of NSAIDs therapy. This was partly 
because of the suggestion that, once developed, gastric 
mucosal lesions may possibly be repaired through the 
administration of NSAIDs for several weeks because of 
adaptation.
21,22 However, it was reported that a longer 
period, as well as a larger dose, of NSAIDs therapy 
could cause an increase in the incidence,
23 suggesting 
that monitoring with periodic endoscopy and blood 
examinations would be needed in patients requiring 
long-term NSAIDs therapy.346  H. Yajima et al.: NSAIDs risk current status in Japan
The incidence of gastric mucosal lesions in patients 
receiving NSAIDs demonstrated in this study was 
similar to that reported by Shiokawa et al.
3 even though 
the patients’ medical history was slightly different. 
During the past decade, it is notable that these results 
were obtained despite the fact that NSAIDs have been 
developed and improved. Under the current circum-
stances, many patients receiving NSAIDs have a high 
possibility of developing gastric mucosal lesions. In any 
case, gastric mucosal lesions are often asymptomatic 
in patients receiving NSAIDs; therefore, orthopedists 
should control pain with NSAIDs with a keen recogni-
tion that greater awareness of the risk of gastric mucosal 
lesions and measures for them are essential even if there 
are no complaints.
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